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ABSTRACT  
Now a days, fast dissolving dosage forms are gaining popularity, as this dosage form can be administered without water. Rapid dissolving 
property, avoiding first pass metabolism and majority of the drug is absorbed through buccal/oral mucosa in to systemic circulation. On oral 
administration of atenolol undergoes first pass metabolism results in reduced bioavailability up to (60%), so the objective of the present study 
was to formulate and evaluate fast dissolving oral films of atenolol to overcome the limitation of bioavailability and increase patient’s 
compliance. In recent studies oral films were prepared by solvent casting method using HPMC K15 as a film formers and PEG 400, glycerin as 
plasticizers and evaluated for mechanical properties, disintegration and in vitro dissolution. Good mechanical properties and in vitro drug 
release were shown by all formulations. The Comparing to other formulations, the optimized (F5) Formulation (HPMC K15, CCS and PEG 400) 
Exhibited drug release of 92.12% in 15 minutes which was significantly high. RP-HPLC is simple, fast, precise, sensitive, and reproducible 
(liquid chromatography) method was developed and validated for the analysis of atenolol drug formulation. Using C-18 HPLC column 
separation was carried out. This was maintained at ambient temperature. Analysis was carried out by using UV detector at the wavelength 228 
nm. The RP-HPLC method was found to be linear over the concentration ranges from 50-100 μg/mL (r2 =0.999). Retention time for atenolol 
drug formulation was found to be 5.496min. LOQ of method was 5.7308μg/mL and LOD 2.5036μg/mL. 
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INTRODUCTION 
In the pharmaceutical industry rapidly dissolving or quick 
dissolving dosage forms have acquired great importance due 
to their unique properties and advantages. Within a minute 
these systems either dissolve or disintegrate, on contact little 
quantity of water or by chewing. This delivery system 
consists of a thin film, which is simply placed on the patient’s 
tongue or mucosal tissue, instantly wet by saliva; the film 
rapidly dissolves. Then it rapidly disintegrates and dissolves 
to release the medication for oral mucosal absorption. The 
major portion of the active ingredient is swallowed orally 
along the saliva and absorption takes place in the 
gastrointestinal tract subsequently making them particularly 
suitable for pediatrics and geriatric patients. In 1970’sthe 
fast dissolving films were introduced as an alternative to the 
conventional tablet and capsule which require swallowing of 
the dosage form1.By researchers the rapidly dissolving 
dosage forms are referred by various names such as quick 
disintegrating, orally disintegrating, mouth dissolve or melt 
in mouth dosage forms. There are specific advantages of 
these dosage forms including no need of water for 
disintegration, accurate dosing, ease of transport, handling, 
acceptable taste, rapid onset of action and patient 
compliance2. The trans mucosal deliveries of metformin, 
dexa-methasone and levo-cetrizine hydrochloride have 
proved their enhanced bioavailability over the conventional 
formulations.8 Solvent casting was proved to be reliable 
technique for the manufacturing of fast dissolving films. By 
this method the film strips prepared undergo instantaneous 
disintegration upon placing in buccal/oral cavity. The 
plasticizers present in fast dissolving films formulation, 
reduce the glass transition temperature and thereby 
enabling desired film qualities3-6. Atenolol is chemically (RS)-
2-{4-[2-Hydroxy-3-(propan-2-ylamino) propoxy] phenyl} 
acetamide. Atenolol is a beta blocker medication primarily 
used to treat high blood pressure and heart-associated chest 
pain. Other uses include the prevention of migraines and 
treatment of certain irregular heart beats. It is taken by 
mouth or by injection into a vein. It can also be used with 
other blood pressure medications. Common side effects 
include feeling tired, heart failure, dizziness, depression, 
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and shortness of breath. Other serious side effects 
include bronchospasm. It is not recommended during 
pregnancy. Other medications are preferred 
when breastfeeding a young baby. It works by blocking β1-
adrenergic receptors in the heart, thus decreasing the heart 
rate and workload. Atenolol is used for a number of 
conditions including hypertension, angina, long QT 
syndrome, acute myocardial infarction, supraventricular 
tachycardia, ventricular tachycardia, and the symptoms 
of alcohol withdrawal. Initial investigations were focused on 
the development of placebo fast dissolving films with good 
peel ability, appearance and a quick disintegration time. 
After choosing the components for the placebo film, atenolol 
loaded films were formulated. Although, fast dissolving film 
is an attractive dosage form for the delivery of atenolol. 
Finally, HPMC and CCS were formulated and evaluated using 
fast dissolving films9. 
MATERIAL AND METHOD  
Atenolol was received as a gift sample from Mylan 
Laboratories Limited, Hyderabad, India. HPLC grade 
methanol, ethanol and double distilled water as solvent were 
used for the other purpose. HPMC K15M, PEG-400, SSG, CCS 
was obtained from Mapromax, Life sciences Pvt. Ltd. 
Dehradun. Aspartame, citric acid was obtained from Loba 
Chemical Pvt Ltd (Mumbai, India). Hydrochloric acid was 
obtained from S. D. Fine Chem. Ltd., Mumbai. All other 
chemical were purchased from Hi Media, Mumbai. All other 
chemicals used in this study including those stated were of 
analytical reagent (A.R.) grade. 
 
Drug-excipient compatibility study  
FTIR spectra of pure drugs, polymers used, and blends were 
recorded on KBr disk method using Brukers Alpha 
Spectrophotometer with IR solution software to confirm the 
compatibility between drug and excipient. Sample powder 
was thoroughly mixed by triturating with potassium 
bromide in a glass mortar with pestle and compressed into 
disks in a hydraulic press (Techno search Instruments, 
India). Over a spectral region from 4700 to 400 cm-1 using 
20 scans with 4 cm-1 resolution, FTIR spectra of all the 
samples were recorded. 
Preparation of oral films  
Drug (atenolol) containing fast dissolving films were 
fabricated by the solvent casting method. The optimized 
amount of HPMC was dissolved in 5mL of water and stirrer 
continuously for 1 hour, optimized amount of Plasticizer and 
drug were dissolved in 95 % ethanol and then added to the 
polymeric solution, Polymeric solution was stirred for 30 
min using magnetic stirrer and was kept in undisturbed 
condition till the entrapped air bubbles were removed. The 
aqueous solution was casted in a glass moulds having 2.5 x 
2.5 cm, 10 films area and was dried at controlled room 
temperature (25-30°C, 45 % RH) as well as at increased 
temperature (microwave oven). The film took approximately 
48 hr to dry at controlled room temperature. The dried film 
was carefully removed from the glass plates and was cut into 
size required for testing. The films were stored in air tight 
plastic bags till further use. Formulations were prepared 
using HPMC K15, PEG-400, SSG and CCS at different drug: 
polymer ratios2, 5-6. The compositions of the formulations 
were shown in table 1. 
 
Table 1. Formulation of Atenolol oral fast dissolving films 
Name of ingredients 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
Atenolol (mg) 500 500 500 500 500 500 
HPMC K15 (mg) 700 80 1100 700 80 1100 
Glycerin (mg) - - - - - - 
PEG-400 (mg) 80 80 80 80 80 80 
SSG (mg) 150 200 300 - - - 
CCS (mg) - - - 200 300 400 
Aspartame (mg) 50 50 50 50 50 50 
Citric acid (mg) 110 110 110 110 110 110 
DM water qs to (ml) - - - - - - 
 
Evaluation  
The formulations were evaluated by the following tests.  
Thickness  
Randomly 20 films were selected and thickness was 
measured using vernier caliber at three different places.  
Weight variation  
For each formulation, three randomly selected patches were 
used. For weight variation test, 20 films from each batch 
were weighed individually by digital electronic balance and 
the average weight was calculated.  
Drug content analysis  
The patches (n = 3) of specified area were taken into a 10 ml 
volumetric flask and dissolved in methanol and volume was 
made up with 10 ml methanol. Subsequent dilutions were 
made and analyzed by UV spectrophotometer. 
 
Folding endurance  
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film could 
be folded at the same place without breaking cracking gave 
the value of folding endurance.  
Percentage of moisture content  
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight.  
In vitro dissolution study  
The in vitro dissolution test was performed using the 
USPXXX dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5°C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 
6.8). Film size required for dose delivery (2.5×2.5 cm2) was 
used. Five ml aliquot of dissolution media was collected at 
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time intervals of 1, 2, 5, 10 and 15 minutes and replaced 
with equal volumes of phosphate buffer (pH 6.8). The 
collected samples were filtered through 0.45 μm membrane 
filter and the concentration of the dissolved atenolol was 
determined using UV-Visible spectrophotometer at 228nm. 
The results were presented as an average of three such 
concentrations4. 
Stability studies  
Stability studies were carried out with optimized 
formulation which was stored for a period of one, two and 
three months at 40±2oC temperature and 75±5% relative 
humidity for a period 3 months. The % Assay of formulation 
was determined by U.V. spectrophotometer using calibration 
curve method. The % assay of film was found to slightly 
decrease at higher temperature.  
Physical appearance and texture analysis of the films  
These parameters were checked simply with visual infection 
of films and by feel or touch.  
In vitro disintegration  
The film of (4.15cm2) size (unit dose) was placed on a 
Petridis containing 10 ml of distilled water. The time 
required for the film to break was noted as cursive in vitro 
disintegration time.  
Measurement of mechanical properties  
Microprocessor based advanced force gauge tensiometer 
(DS 2 series) equipped with a 50 kg 
load cell was used to determine the mechanical properties of 
OFDFs. Film of 60x10 mm2 was fixed between two clamps 
separated by a distance of 3 cm17. The lower clamp was 
held stationary and the strips were pulled apart by the 
upper clamp moving at a rate of 2 mm/sec until the strip 
broke. The force and elongation of the film at the point when 
the strip broke was recorded. The tensile strength and 
percent elongation values were calculated using the 
following formula.  
Tensile strength = load at breakage/film thickness × film 
width  
% Elongation = increase in length ×100/original length  
HPLC METHOD VALIDATION 
Determination of working wavelength (λmax) 
10 mg of atenolol was weighed and transferred in to 100 mL 
volumetric flask and dissolved in methanol and then make a 
dilution of that stock solution. Prepare 10 µg/mL solutions 
by diluting 1 mL to 10 mL with methanol. Wavelength of 
maximum absorption for 10 µg/mL solution of the bulk drug 
in methanol was scanned using UV-Visible 
spectrophotometer within the range of 200-400 nm 
wavelength with methanol as reference. The absorption 
curve shows at 228 nm for atenolol formulation11-16. 
Linearity 
For the linearity study were prepared suitable dilution 
(ranging from 50-100 μg /mL) of standard stock solution 
using mobile phase. Though linear response was obtained at 
lower concentrations for atenolol and higher concentration 
range was used to improve signal to noise ratio. Linearity 
was determined by analyzing five working standard 
solutions over the concentration range of 50-100 μg /mL for 
drug formulation concentration17-20. 
Limit of detection (LOD) 
The limit of detection (LOD) is the smallest concentration 
that can be detected but not necessarily quantified as an 
exact value. LOD is calculated from the formula, 
LOD = 3.3σ/s 
Where, σ = standard deviation of the response 
S = slope of the calibration curve. 
Limit of Quantification (LOQ) 
The limit quantification (LOQ) is the lowest amount of 
analyte in the sample that can be quantitatively determined 
with precision and accuracy. LOQ is calculated from formula, 
LOQ = 10σ/s 
Where, σ = standard deviation of the response 
S = slope of calibration curve 
Accuracy 
Accuracy of this method was carried out using one set of 
different standard addition methods at different 
concentration levels80%, 100% and 120%, and then 
comparing the difference between the spiked value 
(theoretical value) and actual found value. 
Precision 
Five sets of aliquots with same concentration (90 μg /mL) 
were prepared and these solutions were analyzed to record 
any intra and inter day variations in the results. The results 
obtained for Intra and inter day variations. 
Robustness 
Robustness of the proposed method for atenolol was carried 
out by the slight variation in flow rate, temperature and 
mobile phase ratio. The percentage recovery and RSD were 
noted for atenolol. 
Checking resolution of formulation 
The column was saturated with the mobile phase (indicated 
by constant back pressure at desired flow rate). Standard 
solution of atenolol was injected to get the chromatogram. 
The retention time for atenolol was found to be 5.496 min. It 
is shown in the Table 2. 
 
Table 2. Resolution of formulation 
Formulation Ret. Time Area Height Theoretical plate Tailing factor 
Atenolol 5.496 37957814 350811 3806.216 1.02 
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Linearity: 
The data of the peak area vs drug formulation concentration 
were evaluated by linear regression analysis as shown in the 
Table 3 and calibration curve obtained after plotting drug 
formulation concentration vs area shown in the fig.1 Linear 
regression analysis demonstrated that chromatograph 
response for the drug was highly linear (r2=0.999) in the 
studied concentration range of 50-100 μg/mL. A typical 
chromatogram of atenolol (50 μg/mL) shown in fig. 1. 
 
Fig.1 A typical chromatogram for drug formulation 
concentration (50μg/mL) 
 
Fig.2 Calibration curve of atenolol formulation 
 
Table 3. Calibration of atenolol formulation 
Sr no. Concentration (μg /mL) Peak area 
1 50 37957814 
2 60 47957814 
3 70 57987814 
4 80 68907814 
5 90 78957814 
6 100 88957814 
 
Precision 
The result depicted in the table 6a, 6b indicated that the 
given method has sufficient precision as indicated by the 
corresponding values of %RSD ranging 0.13 for inter day 
studies respectively. The values of %RSD for both the studies 
are well below 1.0% constructing adequate precision. 
Limit of detection and quantification 
Standard error and slope of linear data is used to predict 
LOD and LOQ of atenolol and precision was established at the 
predict concentration. The result was shown in the table 7. 
RESULT AND DISCUSSION 
Solubility of atenolol was freely soluble in various solvents 
like methanol and ethanol, also slightly soluble in 0.1N NaOH, 
soluble in water, 0.1N HCL and 6.8 pH phosphate buffers. The 
melting point of atenolol was 220-226ºC and λ max of 
atenolol was found to be 228.0 nm by using U.V. 
spectrophotometer (shimadzu-1800) the general 
appearance, assay, weight variation and thickness of all the 
films were within acceptable limits table 4. The results for 
tensile strength, folding endurance, disintegrating time, % 
elongation and % of moisture were shown in table 5. Tensile 
strength value of optimized formulation (F5) was 
1.324±0.065 kg/cm2 and percent elongation 6.57±0.62. The 
folding endurance of the optimized oral fast dissolving 
formulation (F5) was 132.35±6.45. The formulations 
containing CCS were showing good results compared to SSG. 
The assay values of all the formulations were ranging from 
90.25 to 98.89 %. The disintegration time was ranging 
between 52 to more than 92 sec. The final formulation shows 
better drug release (92.12%) compared to other formulation 
within 15 min(Figure 3).From the stability studies it was 
clearly observed that the drug showed good stability after 
subjecting to accelerated stress conditions and the polymers 
shown significantly compatibility with the drug. The 
cumulative percentage (%) drug release profile and the 
assay of the F5 formulation films indicates that the drug 
remain stable under the ASC without any significant change 
in its release profile and the drug content..RP-HPLC methods 
were developed and validated as per ICH guidelines Q2 (R1). 
The proposed methods can be successfully applied for 
atenolol Fast Dissolving Oral Film without any interference 
in quality control. 
 
Fig.3 In- vitro drug release study of Atenolol formulation
 
Table 4. Result of thickness and weight variation 
F. code General Appearance Thickness in μm Weight(mg) Mean 
± S.D 
% Assay 
F1 Translucent 88±2 155±4 90.25±0.14 
F2 Translucent 90±5 158±3 96.45±0.28 
F3 Translucent 92±5 150±1 95.65±0.36 
F4 Translucent 94±6 152±2 97.65±0.24 
F5 Translucent 95±4 159±5 98.89±0.14 
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Table 5 Result of folding endurance, disintegrating time, tensile strength, % elongation &% of moisture content 
Code Folding 
endurance 
(Times) 
Disintegrating 
time (Sec) 
Tensile strength 
in kg/cm2 
% 
elongation 
Mean ± S.D 
% of moisture 
content 
F1 103.33 ± 9.87 92±4 0.620±0.056 5.94 ± 0.88 0.698±0.111 
F2 105.25 ± 4.56 80±6 0.680±0.045 4.29 ± 0.67 0.647±0.101 
F3 99.33 ± 7.67 75±7 1.212±0.012 2.24 ± 0.57 0.897±0.142 
F4 111.02 ± 8.55 60±6 1.542±0.045 4.35 ± 0.66 0.998±0.156 
F5 132.35 ± 6.45 52±4 1.324±0.065 6.57 ± 0.62 0.898±0.136 
F6 120.66 ± 5.29 55±5 1.269±0.045 3.21 ± 0.21 0.956±0.145 
 
Table 6a. Intra-day Precision for atenolol formulation 
Concentration (μg /mL) Peak area Mean (n=5) S.D. %RSD 
90 78957814    
90 75620844    
90 78528703 77468861 12822.96 0.14 
90 76429855    
90 75069865    
 
Table 6b. Inter-day Precision for atenolol formulation 
Concentration (μg /mL) Peak area Mean (n=5) S.D. %RSD 
90 78957745    
90 75620896    
90 78528756 75100789 38917.53 0.15 
90 76429789    
90 75069896    
 
Table 7 Limit of detection and Limit of quantification 
Limit of detection Limit of quantification 
2.5036μg/mL 5.7308μg/mL 
 
 
CONCLUSION 
Oral fast dissolving films are more superior method to 
release drug. By using HPMC and PEG 400, the films are 
prepared and have shown good mechanical strength, to 
release drug, disintegrate the drug fast and also 
enhancement of stability of drug. From result F5 formulation 
is considered as the best according to got result with low 
disintegration time and complete the drug release with in 15 
min. the percent drug release and disintegration time was 
taken as responses for study which were found within the 
accepted ranges. In these formulation as the concentration of 
CCS was increased, both the disintegration and the drug 
release rates also increased. The disintegration and release 
rates were found to be faster for films prepared with lowest 
concentration of HPMC also with maximum concentration of 
super disintegrates. For pediatric, geriatric and also for 
general population, atenolol being administered in the form 
of fast dissolving films will be potential novel drug dosage 
form by providing faster release and better patient 
compliance. In this paper described for the determination of 
atenolol in formulation is simple, sensitive and reproducible. 
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